SOURCE-LINKED STUDY SUMMARY
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
Abstract summarizedQuality not appraised
- What was studied
- LEAD-6 was a randomized, open-label human trial comparing liraglutide with exenatide. The primary outcome was change in HbA1c, a measure of longer-term blood glucose.
- Who / model studied
- Adults had inadequately controlled type 2 diabetes despite metformin, a sulphonylurea, or both; 233 received liraglutide and 231 exenatide.
- Studied dose & schedule
- For 26 weeks, added treatment was liraglutide 1.8 mg daily or exenatide 10 micrograms twice daily.
- What the study found
- HbA1c fell 1.12 versus 0.79 percentage points. Weight loss was similar. Liraglutide caused less persistent nausea and fewer minor low-glucose events, but controlled glucose after breakfast and dinner less effectively. Two exenatide-plus-sulphonylurea patients had major low-glucose episodes.
- Limitations & context
- Treatment was open-label and lasted 26 weeks. No author-stated limitation was available in this abstract.
Read summary source ↗ · Prepared 9/23/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s0140-6736(09)60659-0